Jalaeefar Amirmohsen, Moini Ashraf, Eslami Bita, Alipour Sadaf, Shirkhoda Mohammad, Aryan Arvin, Mahmoodzadeh Habibollah, Omranipour Ramesh
Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran.
Int J Reprod Biomed. 2021 Feb 21;19(2):181-190. doi: 10.18502/ijrm.v19i2.8476. eCollection 2021 Feb.
Anti-Müllerian hormone (AMH) is a known sensitive biomarker for fertility and ovarian reserve. The results of in vivo and human studies showed inconsistency with respect to the relation between AMH and breast cancer.
To compare the AMH level of young Iranian women with early breast cancer who have not received any treatment compared to that of healthy women.
In this case-control study, 58 breast cancer cases were recruited from the breast oncology clinic of two university hospitals. They were diagnosed with an in situ or invasive breast cancer before any anticancer treatment between August 2018 and April 2019. Healthy controls (n = 58) were selected from women referred to a gynecologic outpatient clinic without any symptoms of cancer or infertility. AMH was measured by the AMH enzyme-linked immunosorbent assay kits in one laboratory.
Final analysis showed that the AMH means of case and control were not statistically significant (3.36 2.95 vs 3.13 1.79). However, the lower and higher AMH level categories are more prevalent in breast cancer compared to the control. Pearson's correlation test showed that the AMH level was negatively correlated with age (r = -0.44, p 0.001). The results of logistic regression analysis considering confounding factors showed the positive association between breast cancer and lower (Odds Ratio [OR] = 5.98, p = 0.02) and higher quartile of AMH level (OR = 4.95, p = 0.01).
Our results suggest that abnormal AMH level is more frequent in young breast cancer patients. Further investigation considering AMH determinants is required.
抗苗勒管激素（AMH）是一种已知的生育能力和卵巢储备的敏感生物标志物。体内研究和人体研究结果在AMH与乳腺癌的关系方面显示出不一致性。
比较未接受任何治疗的伊朗早期乳腺癌年轻女性与健康女性的AMH水平。
在这项病例对照研究中，从两家大学医院的乳腺肿瘤门诊招募了58例乳腺癌病例。她们在2018年8月至2019年4月期间在接受任何抗癌治疗之前被诊断为原位或浸润性乳腺癌。健康对照（n = 58）选自前往妇科门诊且无任何癌症或不孕症状的女性。在一个实验室中使用AMH酶联免疫吸附测定试剂盒测量AMH。
最终分析表明，病例组和对照组的AMH平均值无统计学意义（3.36 ± 2.95 vs 3.13 ± 1.79）。然而，与对照组相比，较低和较高AMH水平类别在乳腺癌中更为普遍。Pearson相关性检验表明，AMH水平与年龄呈负相关（r = -0.44，p < 0.001）。考虑混杂因素的逻辑回归分析结果显示，乳腺癌与较低（比值比[OR] = 5.98，p = 0.02）和较高四分位数的AMH水平（OR = 4.95，p = 0.01）呈正相关。
我们的结果表明，年轻乳腺癌患者中AMH水平异常更为常见。需要进一步研究AMH的决定因素。
